A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
Clinical trial NCT03521154 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03521154
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-19
- Primary completion
- 2024-01-05
- Enrollment
- 216
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.